Top 50 Life Science Startup Investors in Europe (November 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
54 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $25k–$5M |
|
Bpifrance
VC Fund
|
29 | France, United States, Switzerland | Seed, Venture - Series Unknown, Series A | Software, Health Care, Biotechnology | $752k–$34M |
|
Parkwalk Advisors
VC Fund
|
24 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $991k–$44M |
|
Sofinnova Partners
VC Fund
|
23 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
UK Innovation & Science Seed Fund
VC Fund
|
17 | United Kingdom, United States | Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $512k–$6.7M |
|
Oxford Science Enterprises
VC Fund
|
17 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $1.3M–$168M |
|
Future Planet Capital
VC Fund
|
14 | United Kingdom, United States, Singapore | Seed, Series A | Biotechnology, Health Care, Software | $482k–$20M |
|
SOSV SF & NY (Fka IndieBio)
VC Fund
|
13 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Medical | $50k–$5M |
|
Novo Holdings
VC Fund
|
13 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
Kurma Partners
VC Fund
|
12 | France, Switzerland, The Netherlands | Series A, Seed, Series B | Health Care, Biotechnology, Pharmaceutical | $2.8M–$98M |
|
Syncona Partners LLP
VC Fund
|
12 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.9M–$156M |
|
Meusinvest (Noshaq)
VC Fund
|
12 | Belgium, France, Germany | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $159k–$16M |
|
Development Bank of Wales
VC Fund
|
11 | United Kingdom, Australia, United States | Seed, Debt Financing, Venture - Series Unknown | Software, Manufacturing, Health Care | $19k–$5.9M |
|
Seventure Partners
VC Fund
|
11 | France, United States, Germany | Series A, Series B, Seed | Biotechnology, Software, Health Care | $1.1M–$63M |
|
IQ Capital
VC Fund
|
11 | United Kingdom, United States, Germany | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Machine Learning | $744k–$40M |
|
24 Haymarket
VC Fund
|
11 | United Kingdom, United States | Venture - Series Unknown, Seed, Series A | Health Care, Software, Biotechnology | $116k–$16M |
|
Jonathan Milner
Angel
|
11 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $505k–$56M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
11 | Germany, Switzerland, United States | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Health Care | $680k–$31M |
|
Techstart Ventures
VC Fund
|
9 | United Kingdom, United States, Ireland | Seed, Pre-Seed, Venture - Series Unknown | Software, Information Technology, Artificial Intelligence | $197k–$5.7M |
|
Selvedge Venture
VC Fund
|
9 | United Kingdom, United States, Canada | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $1.1M–$30M |
|
Scottish Enterprise
VC Fund
|
9 | United Kingdom, United States, Switzerland | Grant, Seed, Venture - Series Unknown | Biotechnology, Software, Health Care | $119k–$6.3M |
|
Entrepreneurs First
VC Fund
|
9 | United Kingdom, Singapore, United States | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, Machine Learning | $54k–$41M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
9 | Spain, United States, United Kingdom | Grant, Seed, Venture - Series Unknown | Biotechnology, Health Care, Software | $167k–$26M |
|
European Investment Bank
VC Fund
|
9 | France, Germany, Spain | Debt Financing, Post-IPO Debt, Venture - Series Unknown | Energy, Biotechnology, Health Care | $8.7M–$587M |
|
Idinvest Partners
VC Fund
|
9 | France, United States, Germany | Series A, Series B, Venture - Series Unknown | Software, Health Care, Biotechnology | $2.2M–$66M |
|
Calculus Capital
VC Fund
|
8 | United Kingdom, United States, Ireland | Venture - Series Unknown, Series A | Biotechnology, Software, Medical | $1.7M–$10M |
|
Capital Cell
VC Fund
|
8 | Spain, France, United States | Equity Crowdfunding, Seed, Venture - Series Unknown | Health Care, Biotechnology, Medical | $138k–$3.9M |
|
Bullnet Capital
VC Fund
|
8 | Spain, United States, Mexico | Seed, Series A | Software, Manufacturing, Information Technology | $567k–$11M |
|
GM&C Life Sciences Fund
VC Fund
|
8 | United Kingdom, Italy, Germany | Seed, Venture - Series Unknown, Series A | Health Care, Biotechnology, Medical | $94k–$5.8M |
|
Antler
VC Fund
|
8 | United States, Singapore, Australia | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $100k–$29M |
|
Maven Capital Partners
VC Fund
|
8 | United Kingdom, United States, Germany | Venture - Series Unknown, Seed, Private Equity | Software, Information Technology, Manufacturing | $648k–$13M |
|
Advent Life Sciences
VC Fund
|
8 | United States, United Kingdom, France | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $5.5M–$97M |
|
Newable Private Investing
VC Fund
|
8 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.6M |
|
Angels in MedCity
VC Fund
|
8 | United Kingdom, United States | Seed, Venture - Series Unknown, Angel | Health Care, Biotechnology, Medical | $313k–$2.1M |
|
Scottish Investment Bank
VC Fund
|
8 | United Kingdom, United States, France | Venture - Series Unknown, Seed, Series A | Software, Biotechnology, Information Technology | $179k–$7.5M |
|
O2h Ventures
VC Fund
|
8 | United Kingdom, Hungary | Seed, Venture - Series Unknown, Series A | Biotechnology, Health Care, Pharmaceutical | $603k–$25M |
|
APEX Ventures
VC Fund
|
7 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $552k–$28M |
|
Amadeus Capital Partners
VC Fund
|
7 | United Kingdom, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $800k–$60M |
|
Amino Collective
VC Fund
|
7 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
Nina Capital
VC Fund
|
7 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $529k–$21M |
|
Archangels
VC Fund
|
7 | United Kingdom, United States | Venture - Series Unknown, Seed | Software, Health Care, Biotechnology | $795k–$6.6M |
|
IP Group
VC Fund
|
7 | United Kingdom, United States, Australia | Seed, Series A, Series B | Biotechnology, Health Care, Software | $44k–$68M |
|
Enterprise Ireland
VC Fund
|
7 | Ireland, United States, United Kingdom | Seed, Venture - Series Unknown, Grant | Software, Health Care, Information Technology | $26k–$8.2M |
|
BeAble Capital
VC Fund
|
7 | Spain, Italy | Pre-Seed, Seed, Venture - Series Unknown | Biotechnology, Manufacturing, Life Science | $132k–$16M |
|
Kindred Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.4M–$73M |
|
Seedcamp
VC Fund
|
6 | United Kingdom, United States, France | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $469k–$30M |
|
Practica Capital
VC Fund
|
6 | Lithuania, United Kingdom, United States | Seed, Pre-Seed, Series A | Software, B2B, Information Technology | $219k–$30M |
|
Google Ventures
VC Fund
|
6 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$125M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
6 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Lundbeckfonden Ventures
VC Fund
|
6 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
| Access all 50 investors in Europe Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3821
- Round size: Seed $125k–$5M; Pre-Seed $25k–$1.5M; Convertible Note $50k–$3.6M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
- Samphire Neuroscience — Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1745
- Round size: Seed $752k–$6.1M; Series A $2.6M–$34M; Venture - Series Unknown $1.1M–$32M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $27M in 2025
Portfolio highlights
- Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
- Advicenne — Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
- BiPER Therapeutics — BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 356
- Round size: Seed $991k–$4.9M; Series A $1.6M–$14M; Series B $1.7M–$44M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Adsilico — Explore how virtual populations and in silico trials help medical device teams understand variation and build stronger evidence.
- Illumion — Illumion develops high-throughput optical tools to accelerate battery material development
- MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 360
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- IMIO — Improve efficiency across the crop nutrient cycle. IMIO natural microbial products reliably increase nutrient availability and reduce tillage.
- DMC Biotechnologies — Transforming How the World Makes Chemicals
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, United States
Investor stats
- Total investments: 151
- Round size: Seed $512k–$5.9M; Venture - Series Unknown $1M–$6.7M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- StandardX — StandardX is a deep-tech company building the isotope refinery powered by a scalable, compact particle accelerator platform.
- SILVIA BIO — SilVia Bio develops technologies to analyze and optimize mammalian cell factories used in biomanufacturing. The company focuses on identifying critical parameters that limit bioproduction yield and product quality in cell systems such as CHO and HEK cells. Its platform provides cell profiling services that generate interpretable data on manufacturing-relevant bottlenecks. Based on these insights, SilVia Bio designs and supplies precision media additives formulated to address specific rate-limiting cellular processes. The offerings are intended for biopharmaceutical and biomanufacturing teams seeking to improve titre, cell performance, and consistency in production processes. SilVia Bio also collaborates with industrial partners to apply its platform within real manufacturing environments.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 210
- Round size: Seed $1.3M–$12M; Series A $6.3M–$45M; Series B $9.1M–$168M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $299M in 2022
Portfolio highlights
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Singapore
Investor stats
- Total investments: 313
- Round size: Seed $482k–$5.1M; Series A $1.4M–$20M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Unloq AI — Unloq is a decision intelligence platform that helps businesses understand why a choice makes sense, what actions to take, and whether they deliver results.
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 676
- Round size: Seed $250k–$5M; Pre-Seed $50k–$525k; Convertible Note $150k–$950k
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Giraffe Bio — Giraffe Bio uses AI and biomolecules to optimize metal extraction, increase yield, and reduce environmental impact. Revolutionizing sustainable mining technology.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 415
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $35M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Vantia Therapeutics — Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovations in Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, The Netherlands
Investor stats
- Total investments: 146
- Round size: Seed $2.8M–$14M; Series A $3.9M–$98M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $236M in 2024
Portfolio highlights
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Seed $1.9M–$17M; Series A $13M–$87M; Series B $29M–$156M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Re-Aim Therapeutics — Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 82
- Round size: Seed $159k–$6M; Series A $3.6M–$16M; Venture - Series Unknown $946k–$16M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Manufacturing, Health Care
- Stage:Seed, Debt Financing, Venture - Series Unknown
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 301
- Round size: Seed $327k–$2.5M; Debt Financing $19k–$3.7M; Venture - Series Unknown $383k–$5.9M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — raised $27M in 2018
Portfolio highlights
- Design and Supply — Design and Supply provides products and services primarily for the construction industry, offering Jansen-certified products and British SBD solutions. The company manufactures and supplies items, including steel doors. Additionally, Design and Supply caters to design enthusiasts by offering artwork, fine furniture, antiques, and decor.
- MeOmics Technology — MeOmics Technology is a biotech company with a focus on improving the diagnosis and treatment of mental health illnesses. The company operates in the manufacturing industry and has a team of 9 employees. The team includes experts in Neuronal Cell Biology and Neuropsychopharmacology. The company's mission is to leverage technology to enhancethe understanding and treatment of mental health conditions.
- Outlook Expeditions — Outlook Expeditions provide overseas educational expeditions, adventure travel and service-learning projects for schools.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion. Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion under management as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations. Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors. The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, United States, Germany
Investor stats
- Total investments: 281
- Round size: Seed $1.1M–$4.7M; Series A $3.3M–$24M; Series B $3.3M–$63M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Flexvelop — Flexvelop is a fintech transforming the way businesses finance essential business equipment. "Flexing" is an innovative combination of leasing, renting and bank-financing terms offering a kind of Hardware-as-a-Service solution. Embedded as a payment solution, partnered manufacturers, vendors and brands are actively offering"Flexing" to their b2b customers for financing new business equipment right at the point of sale and in online shops. Flexvelop is operating in the verticals of office-it, hospitality equipment, medical devices or fitness equipment throughout Germany. Well-known manufacturers like Lenovo, WMF, or LaMarzocco are using Flexing openly or as a white-label solution. SMB customers flex equipment to grow flexibly without the usual investment risk – saving liquidity, tax and a clean balance sheet. Flexvelop is using its patented in-house financing technology, promoting a more sustainable circular economy in the same time. Flexing becomes the new standard for business equipment procurement for SMBs throughout Germany, Europe and beyond.
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
IQ Capital is a dedicated European deep tech venture capital firm, built on the conviction that frontier technology will underpin the next generation of globally significant companies. We back founders leveraging scientific breakthroughs to build enduring global businesses. We have invested in over 100 of Europe's most ambitious deep tech teams across six funds since 2005.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 216
- Round size: Seed $1.3M–$13M; Series A $4.7M–$40M; Venture - Series Unknown $744k–$9.2M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Mindgard — Mindgard is the leading provider of AI Red Teaming solutions.
- Imperagen — Imperagen is a biotechnology research company focused on enzyme engineering, artificial intelligence, and synthetic biology.
- Undecimal Bio — Undecimal Bio operates as a platform biotechnology company that develops targeted delivery mechanisms for small interfering RNA (siRNA) therapeutics. The company utilizes a proprietary platform that combines combinatorial chemistry libraries with transformer-based artificial intelligence to discover molecular conjugates capable of guiding genetic medicines to specified cells outside of the liver. This approach aims to circumvent traditional delivery constraints to expand the reach of RNA therapeutics into a broader range of therapeutic areas and human organs.
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growth agenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 108
- Round size: Seed $736k–$3.7M; Series A $1.8M–$16M; Venture - Series Unknown $116k–$4.3M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- WATR — WATR is the integrated system for real-time water or soil quality monitoring. Our products are robust, reliable, accurate, easy to use and benchmarked for accuracy.
- Dogtooth — Dogtooth is a Cambridge-based technology start-up that sells state-of-the-art intelligent robots for soft fruit picking.
- Previsico — Live, property-level surface water and flash flood forecasting. Previsico gives insurers, brokers and large organisations 48-hour advance flood warnings - specific enough to act on, proven to mitigate losses.
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon Discovery Group plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 63
- Round size: Seed $505k–$25M; Series A $4.5M–$50M; Series B $1.6M–$56M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 470+ centers worldwide.
- Nuclera — Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in various sectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 851
- Round size: Seed $680k–$6.5M; Series A $3M–$31M; Venture - Series Unknown $911k–$12M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
- Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
Techstart Ventures is a first-cheque investor for extraordinary founders pursuing uncapped global opportunities.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 212
- Round size: Seed $221k–$4M; Pre-Seed $197k–$1.3M; Venture - Series Unknown $477k–$5.7M
- Lead/follow: 51% lead, 49% follow
Portfolio highlights
- Go Swag — Branded swag people want to keep, designed, sourced, stored and delivered by one team to 180+ countries. Managed programmes, Studio projects and Select.
- Saltroad — Get matched with an experienced HCPC Speech and Language Therapist based on your child's needs, your budget and your schedule. Loved by parents & children.
- Farmdrive — Farmdrive helps supply chain partners create transparent, effective, and resilient operations from farm to shelf by streamlining data collection and simplifying farm management.
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 20
- Round size: Seed $1.4M–$9.6M; Pre-Seed $1.1M–$2.5M; Series A $3.5M–$30M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Mesh Bio — We enable digital transformation of care delivery through clinical workflow automation and predictive analytics, built on gold standard clinical guidelines and best practices.
- BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
- MultiOmic Health — AI-Enabled Precision Medicine for Metabolic Syndrome
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed, Venture - Series Unknown
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 410
- Round size: Seed $406k–$4.3M; Grant $119k–$5.3M; Venture - Series Unknown $566k–$6.3M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- GLORIAH — Explore plant-based intimate hydration oils, water-based personal gels, fragrance roll-ons and product sets designed for simple everyday routines.
- SolarSub — SolarSub is an environmental firm that offers floating solar cooling system.
- INEOS O&P USA — INEOS O&P USA specializes in producing raw materials that are essential in the manufacture of a wide variety of goods under various sectors.
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Singapore, United States
Investor stats
- Total investments: 485
- Round size: Seed $54k–$6.7M; Pre-Seed $55k–$2.7M; Series A $5.1M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $133M in 2026
Portfolio highlights
- ByteAsk — Derisk your AI agents
- Sourcepulse — Your early warning system for software delivery (YC S23)
- Open Cosmos — Open Cosmos design, build and operate space missions, providing straightforward access to high quality satellite data and insights on a global scale.
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national and international levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed, Venture - Series Unknown
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 225
- Round size: Seed $619k–$5.8M; Grant $167k–$15M; Venture - Series Unknown $846k–$26M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- EpiDisease — EpiDisease provides biomedical solutions, epigenetic diagnostic tools, and characterization of new epigenetic drugs. The company was founded in 2014 and based in Paterna, Comunidad Valenciana, Spain.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
- Connecta Therapeutics — Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome.
European Investment Bank operates as the lending institution of the European Union, offering loans, guarantees, and technical expertise to governments, businesses, and financial institutions. The organization focuses on areas such as climate action, digital transformation, housing development, and security-related initiatives. Its activities include funding large-scale infrastructure, supporting technology development, and facilitating access to capital for emerging and established enterprises. The bank also delivers advisory support to structure projects, improve investment readiness, and align initiatives with policy objectives.
Show more...Investment focus
- Industry: Energy, Biotechnology, Health Care
- Stage:Debt Financing, Post-IPO Debt, Venture - Series Unknown
- Geography: France, Germany, Spain
Investor stats
- Total investments: 608
- Round size: Post-IPO Debt $16M–$587M; Debt Financing $16M–$355M; Venture - Series Unknown $8.7M–$110M
- Lead/follow: 82% lead, 18% follow
Portfolio highlights
- Impress — Impress – is European leading digital orthodontic DSO of new generationWe have a defensible model with the personal touch of an in-house orthodontist, true clinical expertise, and engaging directly with consumersImpress was founded in 2019 in Barcelona with the idea of combining the best of orthodontic tradition with the most innovativetechnology in the sector. From the very beginning the vision of the Impress founders was to introduce a different business model with a strong focus on medical experience and digitalization. The company is transforming the oral healthcare industry by developing its own chain of orthodontic clinics, which are characterized by their disruptive design and modern patient experience. The founders decided to build a medical company with the personal touch of in-house orthodontists, face-to-face care, and unique clinical expertise, where the proper implementation of business processes and digitalization are at the core.In less than 2 years, Impress has managed to position itself as the European leader in the orthodontic sector, has treated more than 22.000 smiles and already has a presence in more than 80 European cities. Its innovation and quality have earned it recognition from Sifted as one of the fastest growing HealthTech companies in Europe in 2020.
- Santander Brasil — Banco Santander in Brazil, its largest division in Latin America and one of the world's most important, accounting for 50%.
- Dandara Solar Power SAE — Dandara Solar Power SAE is a special purpose vehicle, established to develop a major renewable energy and storage project in Upper Egypt. The entity oversees the development and operational construction of a 500 MW solar PV plant integrated with a 100 MWh Battery Energy Storage System. All electricity generated by the company is bound to be sold to the industrial manufacturer Misr Aluminum Company under a long term, take or pay power purchase agreement.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primary investments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting. Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: France, United States, Germany
Investor stats
- Total investments: 362
- Round size: Series A $3.4M–$22M; Series B $7.8M–$66M; Venture - Series Unknown $2.2M–$37M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $97M in 2021
Portfolio highlights
- Actility — Actility provides IoT connectivity and solutions to power smart cities and industries.
- Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
- StarTower — StarTower is a resource company built specifically for fully decentralized physical infrastructure and shared interaction. Based on the exclusive RIP encryption technology, StarTower realizes the interactive sharing of multiple resources with zero loss on mobile devices, thereby providing efficient resource transmission for terminal facilities. Itprovides more efficient, secure and reliable solutions in the fields of Internet of Things, smart cities, industrial automation, healthcare, etc.
At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile. They look to make £2-5 million investments in established companies with proven management teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Venture - Series Unknown, Series A
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 82
- Round size: Series A $2.5M–$10M; Venture - Series Unknown $1.7M–$8.3M
- Lead/follow: 66% lead, 34% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Edify Systems — Edify connects ordering, stock, production planning and reporting across your sites, taking on the everyday work so your team can focus on customers.
- Grateful — Grateful provides cashless tipping and trunk management software that integrates QR/NFC, EPOS systems, and compliance reporting.
- Resurrect Bio — Resurrect Bio discovers crop disease-resistance traits, using AI and high-throughput in-planta screening to deliver them to seed companies up to 10x faster.
Capital Cell is a crowdinvesting platform for biotech and life sciences companies. Mixing VC, business angels, accredited investors, and the power of the crowd, the company is building a global meeting point for companies and researchers working, fostering, and financing tomorrow’s medical science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Equity Crowdfunding, Seed, Venture - Series Unknown
- Geography: Spain, France, United States
Investor stats
- Total investments: 53
- Round size: Seed $392k–$1.9M; Equity Crowdfunding $138k–$1.5M; Venture - Series Unknown $617k–$3.9M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- AbTx — Antibody for Therapy
- DYNAMICS VR — Dynamics VR provides rehab software for clinics to tackle musculoskeletal pain and movement impairments caused by brain trauma.
- EVis Bioscience — EVis Bioscience develops innovative gene delivery systems for targeted and personalized medicine. This includes extracellular vesicles, synthetic lipid nanoparticles, and their hybrids.
Independent Venture Capital Firm specialized in high technology Spanish start-ups. Helping tech entrepreneurs during the early stages of their company to build successful businesses
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Seed, Series A
- Geography: Spain, United States, Mexico
Investor stats
- Total investments: 68
- Round size: Seed $1M–$3.2M; Series A $567k–$11M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $87M in 2023
Portfolio highlights
- FlexiiC — Reinventing the world of electronics with a revolutionary organic and flexible technology that enables a new generation of sensors and logic based on solution deposited functional inks at a low temperature, on low-cost substrates to make organic integrated circuits. Products and services FlexiiC presents design modeling services including Application Specific Integrated Circuits (ASIC) and Process ... Read more
- Bioherent — Photonic biosensors for drug allergy diagnosis
- Impetux Optics — Optical tweezers and microscopy systems for Cell Mechanics, Molecular Biophysics, Phase Separation and Soft Matter Physics applications
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 36
- Round size: Seed $94k–$1.9M; Series A $1.9M–$4.2M; Venture - Series Unknown $4.3M–$5.8M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
- Infex Therapeutics — Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, Singapore, Australia
Investor stats
- Total investments: 2394
- Round size: Seed $159k–$4.6M; Pre-Seed $100k–$611k; Series A $4.1M–$29M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $7.5M in 2026
Portfolio highlights
- Praktiki — Praktiki is the AI platform for medical education: expert-led, case-based 5-minute modules HCPs love, built in hours and measured for behaviour change.
- ReportsAI — ReportsAI is an impact operating system that automates data collection and reporting for NGOs and industry to ensure audit-ready compliance.
- Plouton AI —
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Maven is one of the UK's leading private equity and investment firms. We provide essential capital and expertise to help businesses unlock their potential.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Venture - Series Unknown, Seed, Private Equity
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 239
- Round size: Seed $783k–$5M; Private Equity $1.1M–$13M; Venture - Series Unknown $648k–$8.3M
- Lead/follow: 74% lead, 26% follow
- Last fund: May invest from a new fund soon — raised $132M in 2019
Portfolio highlights
- KubeNet — We are KubeNet - a multi-award winning technology solutions provider based in Glasgow. Whether it's Managed IT, IT Support, Cloud, Connectivity, Voice or Cyber Security, we're by your side as your trusted technology partner.
- Tixserve — Secure, Trackable, Interactive Digital Tickets for Live Events
- ReadyGo Diagnostics — ReadyGo Diagnostics has invented a novel “Diagnostic Pen”. Low cost, intuitive to use from the raw sample, the ReadyGo Pen will be a game-changer in the newly emerging consumer diagnostics market, offering a yes/no answer in minutes, based on molecular analysis.
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 74
- Round size: Series A $5.5M–$51M; Series B $21M–$97M; Venture - Series Unknown $7M–$80M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
- Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Newable exists to power business growth. Our strategy of Buy, Grow, Realise focuses on the regulated B2B market.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 110
- Round size: Seed $196k–$3.2M; Series A $1.5M–$5.6M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
- Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
- EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies. With a particular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas. Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Venture - Series Unknown, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 20
- Round size: Seed $482k–$2M; Angel $313k–$1.2M; Venture - Series Unknown $1.1M–$2.1M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Calira — Calira (formerly Clustermarket). Give researchers an easy way to book equipment, improve equipment utilisation, and get structured lab usage data.
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
Speak with our team, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 314
- Round size: Seed $331k–$3.2M; Series A $1.7M–$7.5M; Venture - Series Unknown $179k–$4.1M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Corvidae — Corvidae is a software company that provides data analysts, digital marketing, e commerce, and paid media solutions.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- RoslinCT — We are the prefered global partner for cell and gene therapy solutions. With our wealth of expertise and infrastructure, we can support you at every step of your advanced therapy journey.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 60
- Round size: Seed $603k–$7.3M; Series A $1.9M–$25M; Venture - Series Unknown $1.1M–$2.9M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Healx — Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io.
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
APEX Ventures is a deep-tech and medical focused venture capital firm, run by founders with complimentary backgrounds driven by the same mission.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 62
- Round size: Seed $1.4M–$8M; Pre-Seed $552k–$9.1M; Series A $5.7M–$28M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 470+ centers worldwide.
- iPremom — iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia.
- Jago Coffee — Jago Coffee serves freshly brewed coffee beverages wherever you are through a fleet of fully electric mobile cafes.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 283
- Round size: Seed $800k–$9.2M; Series A $2.6M–$30M; Series B $7.2M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $85M in 2023
Portfolio highlights
- iPremom — iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early detection and prediction of pregnancy complications, particularly preeclampsia.
- Respiro Diagnostics — Respiro is harnessing insights from the breath to detect lung cancer earlier, non-invasively, and without scans or radiation. Built for use in everyday care settings.
- iPronics — iPronics develops the innovative concepts of general-purpose integrated programmable photonic systems.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 47
- Round size: Seed $2.4M–$14M; Pre-Seed $125k–$10M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it.
- Frontier Computing — Frontier Computing is a biocomputing company growing large-scale neuronal tissue, living hardware with memory baked in at the cellular level.
- Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 96
- Round size: Seed $2M–$6.3M; Pre-Seed $529k–$2.4M; Series A $5M–$21M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $52M in 2025
Portfolio highlights
- Biobase — Biobase is the agentic system for clinical data, connecting health systems and life science teams to turn siloed clinical data into research-ready data.
- Ladder Health — Expert speech, occupational, physical, and feeding therapy for children, right from home, with flexible virtual visits and a plan that fits real life.
- Woodway Assurance — Woodway Assurance provides EviData, an AI-driven software for automated privacy assurance on de-identified and synthetic datasets.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Venture - Series Unknown, Seed
- Geography: United Kingdom, United States
Investor stats
- Total investments: 88
- Round size: Seed $1.3M–$6.6M; Venture - Series Unknown $795k–$6.3M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- CSignum — Revolutionising underwater communications with electromagnetic technology for seamless data integration between surface & submerged devices.
- Corvidae — Corvidae is a software company that provides data analysts, digital marketing, e commerce, and paid media solutions.
- iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and create value out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 261
- Round size: Seed $44k–$5.3M; Series A $2.4M–$30M; Series B $7.9M–$68M
- Lead/follow: 20% lead, 80% follow
- Last fund: Likely actively investing — fresh fund, raised $50M in 2026
Portfolio highlights
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- Matter Machine — Matter Machine is an AI-driven materials discovery company that creates technologies that use materials chemistry, machine learning, and automated experimentation to speed up the discovery and optimization of next-generation materials.
- Mach42 — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Grant
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 895
- Round size: Seed $399k–$3.2M; Grant $26k–$5.5M; Venture - Series Unknown $560k–$8.2M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $1.2M in 2021
Portfolio highlights
- Foodcloud — We connect businesses that have surplus food with Charities and Community Groups that need it.
- Amethyst Care — Amethyst Care is a startup that creates an AI-powered voice assistant for those with mobility difficulties.
- EstateMin — EstateMin provides software for law firms handling estate planning, trust administration, probate, and estate administration. Its platform supports client intake, case workflows, document organization, asset and liability tracking, and case progress visibility through a centralized dashboard. A client portal lets clients and executors submit information and documents. The platform also offers AI-supported case review and integrates with Clio.
BeAble Capital is a Science Equity Fund, therefore it is a pre-seed, seed and early stage venture capital management company specialized in the identification, valuation, launch and development of technologies in the sectors of advanced materials (nanotechnology and biotechnology), photonics, micro and nano electronics and Information and communications technologies (ICT) platforms. It acts as the link between scientific, entrepreneurial and investing worlds to promote the transfer of technology, the creation and the development of technology-based companies (start-ups) from private equity. The company is focused on strong intelectual property and long R&D background projects. Their work provide value at different stages of development by offering support in strategic points such as the identification of technologies, valuation, transfer, companies creation, fundraising, marketing, internationalization and administrative and managerial expertise.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Life Science
- Stage:Pre-Seed, Seed, Venture - Series Unknown
- Geography: Spain, Italy
Investor stats
- Total investments: 71
- Round size: Seed $158k–$1.6M; Pre-Seed $132k–$514k; Venture - Series Unknown $889k–$16M
- Lead/follow: 83% lead, 17% follow
- Last fund: May invest from a new fund soon — raised $39M in 2016
Portfolio highlights
- Safeloc Systems — Safeloc Systems is a developer of a real-time location system solution (RTLS) to provide ultra-wideband (UWB) technology services.
- Bioinspired Materials — Bioinspired Materials is a Biotech-based entrepreneurship project with the participation of the Universitat Pompeu Fabra. The company develops wastewater valorization that produces biological products of high value in the market. BIOM was founded in 2019 and is based in Barcelona, Spain.
- Ars Magna Semiconductors — Ars Magna Semiconductors develops semiconductor chips designed for decentralized artificial intelligence applications. The company's technology operates with low energy consumption, real-time processing, and enhanced data privacy by reducing the number of operations and hardware requirements. Their chips address the global semiconductorshortage while enabling more efficient AI processing with reduced computational overhead.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 131
- Round size: Seed $1.4M–$16M; Series A $7.9M–$33M; Series B $8M–$73M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- RobCo — Easily automate the repetitive tasks in your production facility with modular industrial robots from RobCo.
- Bios Life — Bios Life is a technology-enabled healthcare company built to empower individuals to proactively manage their cancer risk, redefining personalized cancer screening and survivorship.
- Scarlet — Scarlet certifies software medical devices. We’re Europe's only Notified Body specialised in software and AI, and have crafted a certification process that is built for software, and is thus significantly more efficient.This is how we deliver on our mission to hasten the world’s transition to accessible healthcare: by enabling manufacturersto release their medical software and AI to those who need it without unnecessary delays.We are designated as a UK Approved Body by the MHRA, and an EU Notified Body by the Dutch Ministry of Health and the European Commission.
By Your Side from Day One
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 668
- Round size: Seed $469k–$8M; Pre-Seed $588k–$3.5M; Series A $5M–$30M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely actively investing — fresh fund, raised $220M in 2026
Portfolio highlights
- i23 — i23 is an insurtech startup that builds an artificial intelligence platform to automate administrative workflows for commercial insurance brokers.
- Solvera AI — Solvera is an AI-native engineering firm on a mission to unleash the potential of every building engineer with AI. It develops advanced proprietary AI systems to help design better buildings, significantly faster, establishing a brand-new standard for MEP engineering.
- Vessla — Vessla is the agentic OS for property operations, where agents and people run work together across the portfolio.
Practica Capital
Show more...Investment focus
- Industry: Software, B2B, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Lithuania, United Kingdom, United States
Investor stats
- Total investments: 157
- Round size: Seed $219k–$3.2M; Pre-Seed $555k–$2.4M; Series A $2.4M–$30M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — raised $85M in 2022
Portfolio highlights
- Creem — Creem is the money platform for the AI era. Sell software and digital products globally.
- kopa.ai — Kopa is the AI Google Ads media buyer that executes after you decide. Syncs with your store, backs every keyword with live Google search volume, audits Search, Shopping, and PMax, disables margin-draining auto-expansion defaults, eliminates wasted search traffic 24/7, and executes what you approve.
- Outcraft AI — Outcraft AI develops autonomous revenue agents that convert, retain and grow customers across voice, SMS, email and messaging.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1582
- Round size: Seed $1.1M–$14M; Series A $6M–$100M; Series B $15M–$125M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- ngmoco — ngmoco ("Next Generation MObile COmpany") is creating and producing games for the iPhone. CEO Neil Young is a former executive from Electronic Arts, where he oversaw the development of several hit titles. Another EA vet and partner at Kleiner Perkins, Bing Gordon, sits on the board. Kleiner is an investor through its iFund.
- SolveAI —
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 74
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $10M–$53M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
- Women in Life Science Denmark — WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Europe Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!